Prediction of Rhizoma Drynariae Targets in the Treatment of Osteoarthritis Based on Network Pharmacology and Experimental Verification

Figure 9

mRNA and protein levels of IL-6 in IL-1β-treated SW1353 cells pretreated with the aqueous extract of Rhizoma Drynariae (AERD) or luteolin. SW1353 cells were pretreated with 625 mg/L, 1250 mg/L, or 2500 mg/L AERD or 7.5 μmol/L, 15 μmol/L, or 30 μmol/L luteolin for 1 h, and then treated with 10 ng/mL IL-1β for 12 h. (a) mRNA expression of IL-6 in IL-1β-treated SW1353 cells pretreated with AERD or luteolin. (b) The protein levels of IL-6 in IL-1β-treated SW1353 cells pretreated with AERD or luteolin. The data are derived from three independent experiments and expressed as the mean ± standard deviation ( < 0.05: increase significantly compared with the control group;  < 0.05: decrease with the concentration of AERD compared with the IL-1β-treated group; and  < 0.05: significance differences between low dose, medium dose, and high dose of luteolin and AERD).

(a)

(b)